LRMR · CIK 0001374690 · FY2025 live · 2025-12-31
Larimar Therapeutics, Inc.
View as
Model
Classic Z
FY2025
−6.75
Zone
Distress
Prior
—
Market DD
—
1y PD
—
−6.75
Z″ −12.98
Score −6.75 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.531.2 × = 0.64X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−2.981.4 × = −4.17X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−1.183.3 × = −3.90X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
1.150.6 × = 0.69X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.001 × = 0.00
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings rather than invent a series.
Overview
rule-v1
Larimar Therapeutics, Inc. is on classic Z at −6.75 (distress) for FY2025, from an SEC 10-K. Retained earnings / assets is the line that sets the print; EBIT / assets is the runner-up. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers; buybacks can send retained earnings negative at otherwise healthy issuers, and X4 is book equity, not market cap.
Book screen Distress; market PD —. Tape not priced — not a single default call.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 23rd percentile in Healthcare.
- SLNDistressSilence Therapeutics plc−6.77
- BBIODistressBridgeBio Pharma, Inc.−6.79
- ABOSDistressAcumen Pharmaceuticals, Inc.−6.71
- CGTXDistressCOGNITION THERAPEUTICS INC−6.71
- NEUPDistressNeuphoria Therapeutics Inc.−6.67
- VANIDistressVivani Medical, Inc.−6.84
- LYELDistressLyell Immunopharma, Inc.−6.91
- CRVODistressCervoMed Inc.−6.58
KPI widgets
Current assets
$142M
Total assets
$146M
Current liabilities
$65M
Total liabilities
$68M
Working capital
$77M
Retained earnings
−$435M
EBIT
−$172M
Total sales
$0
Book equity
$78M
Accession 0001193125-26-115878. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as does not rewrite the live rank. X4 is book equity. Pulled 12 Sept 2026.